Healthcare Reforms Pushes Industry Modernisation

BMI View: We believe Russia's latest healthcare reform law will act as a further modernising force and, due to late-stage amendments, is broadly positive for the pharmaceutical industry. While drugmakers may have to re-examine their marketing strategies in response to the passage of the law, we note that many of the early-stage unfavourable aspects of the legislation relating to contact between drugmakers and healthcare professionals have been dropped. The fact that orphan diseases are now recognised in law is major step forward, but we highlight continued deficiencies in the adopted bill. In the context of demonstrations following the December 4 parliamentary election, we do not believe these actions represent a major shift in the political landscape. In fact, in relation to healthcare, additional government funding may be seen as a tool of appeasement.

To read the full article, please choose one of the following options: